| 2020-SINT-69073 | |
| Purdue University researchers have synthesized kinase inhibitors that display potent anti-proliferative effects when dosed into lung, pancreatic, and colon cancer cells. Overactive kinases are a primary driver of cancer cell proliferation. Accordingly, many chemotherapeutic regimens contain kinase inhibitors; however, current kinase targeting compounds are not effective in treating aggressive forms of lung, pancreatic, and colon cancers. Purdue University researchers have optimized previously identified kinase inhibitors to achieve a higher potency against many lung, pancreatic, and colon cancer cell lines. These compounds were tested against the NCI-60 cancer cell panel and have low sub micromolar GI50 values. For example, the GI50 against some colon cancers are as low as 5 nM. These compounds also have IC50 values of 25 nM against proliferation of the MiaPaCa-2 pancreatic cancer cell line. The potency of the compounds toward multiple aggressive cancer cell lines makes them promising cancer therapeutic candidates for future development. Technology Validation: The compounds were tested against the NCI-60 cancer cell line panel and exhibit nanomolar GI50 values in some cell lines. Advantages -Inhibits Growth of Multiple Cancer Cell Lines -Increased Potency versus Previously Identified Molecules Applications -Cancer Therapies -Cancer Relapse -Kinase Inhibitors |
|
|
|
|
Dec 8, 2022
NATL-Patent
United States
(None)
(None)
Jun 24, 2021
PCT-Patent
WO
(None)
(None)
Jun 24, 2021
NATL-Patent
Europe
(None)
(None)
Jun 24, 2021
NATL-Patent
Canada
(None)
(None)
Jun 24, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
